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 
Abstract—Objective: the study evaluated the clinical and 
echocardiographic data, before and after percutaneous mitral 
commissurotomy (PMC) in patients with calcific mitral 
stenosis.               Materials and methods: this is a retrospective 
study of 215 patients divided into two groups: 148 patients 
with calcific mitral stenosis (Group 1), and 67 patients without 
mitral calcifications (Group 2). The study period is between 
January 2011 to July 2015.Results: the group 1 was 
significantly older than the group 2 (49,7±12,2 (group 1) versus 
42,7±12,8(group 2) , p<0,001), and had significantly more men 
than women (female gender:75% in group 1 vs.88,1% in group 
2, p<0,05). Before PMC: group 1 had significantly higher 
Wilkins (9,3±0,8(group 1) vs. 8,5±0,6 (group 2)   p <0,001) and 
smaller mitral valve area (0,91±0,20 (group1)  vs.0,99±0,20 ( 
group 2), p<0,05). After PMC: the final valve area was 
significantly smaller in patients with, than, without 
calcifications (2,10±0,26 vs.2,20±0,22  p<0,05). However , the 
rate of good immediate results, defined as valve area ≥1,5 cm² 
with no mitral regurgitation >2/4 ( 97,9%vs.100% , p> 0,05), 
and the rate of post PMC mitral regurgitation (MR≥3/4) (2% 
vs.0% , p>0,05), were no different between the 2 
groups.Conclusion: PMC can be used for the treatment of 
patients with calcific mitral stenosis safety, with good 
immediate results.    
Index Terms—Calcification, Echocardiography,Percutaneous 
mitral commissurotomy, Mitral stenosis. 
 
I. INTRODUCTION 
The mitral valve stenosis is the most acquired common 
valvular disease in the countries in development [1,2]. Since 
its introduction in 1984 by Inoue, the percutaneous mitral 
commissurotomy (PMC) has become an effective and 
durable procedure to treat patient with mitral stenosis [3]. 
Today PMC is considered the first line treatment for 
symptomatic patients with favorable anatomy [4, 
5].However, therapeutic decision is discussed when the 
mitral valve stenosis is calcified, and some studies have 
reported a lower PMC success rate and more frequent post 
procedural severe mitral regurgitation (MR) in patients with 
mitral valve calcification [6]. The aim of our study is to 
assess the immediate outcome of PMC in patients with 
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 calcific mitral stenosis. 
II. MATERIALS AND METHODS 
This is a retrospective study included 215 patients with  
mitral valve stenosis , who underwent a PMC between 
January 2011 and July 2015 at cardiology department A in 
IbnSina hospital, Rabat  Morocco. All of them had 
transthoracic echocardiography before and after PMC, and a 
transoesopagic echocardiography before this procedure. 
Exclusion criteria for PMC were severe bilateral 
commissural calcification, more than mild mitral 
regurgitation and left atrial thrombus.  Echocardiography 
was performed just before and 24–48 h after the procedure 
by experienced operators. Mitral valve area (MVA) was 
measured by 2-dimensional echocardiography in parasternal 
short-axis view (planimetry). Mean transmitral gradient was 
assessed by continuous wave Doppler. Measurement of 
systolic pulmonary artery pressure was based on the 
maximal velocity of the tricuspid regurgitation. Mitral 
regurgitation was semi-quantitatively graded from 0 to 4.  
After PMC, the ‘degree of commissural opening’ was semi-
quantitatively evaluated as none, partial (up from only 
several millimetres from the valve orifice), or complete (up 
to the level of the mitral annulus) in parasternal short-axis 
view. Mitral valve calcification was defined using 
transthoracic echocardiography as bright areas with acoustic 
shadowing. The degree of calcification was independently 
scored. Patients were divided into two groups: Group1 with 
calcific mitral stenosis (MS) and Group 2 with non-calcific 
MS. PMC was performed by antero-grade trans-venous 
approach using the Inoue balloon with stepwise inflation 
showed by echocardiography; balloon size was depending 
to patient’s height and the balloon was inflated in steps of 
1–2 mm. Valve area (planimetry), mean transmitral 
gradient, commissural splitting, and the degree of MR were 
assessed by transthoracic echocardiography after each 
inflation. Our criteria for stopping the procedure were 
complete opening of at least one commissure with a valve 
area at 1.5 cm2 or the occurrence or increase of 
regurgitation. A good immediate result was defined as a 
good valve opening (final valve area≥1.5 cm2) with no 
regurgitation.;Quantitative variables were expressed by 
mean ± standard deviation and compared by T-test. 
Qualitative variables were expressed by percent and 
compared by Chi-2 test or Fisher test. Statistic is significant 
by p<0, 05.  
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III. RESULTS 
Mean age was 47±12 years and 79, 5% were female. 
Most of patients were symptomatic and 60% had atrial 
fibrillation, 18, 6% had a previous commissurotomy (either 
surgical or percutaneous).Clinical and echocardiographic 
characteristics of patients are presented in Table 1.  148 
patients had a calcific mitral stenosis (group1) and 67 
patients without mitral calcification (group2)  .Group 1 was 
significantly older than Group 2 (49,7±12,2 versus 
42,7±12,8, P<0,001), and had significantly more men than 
women.(female gender 75% in group 1 Vs 88,1% in group 
2, P<0,05).The incidence of previous commissurotomy was 
similar into the two groups( 24,3% vs11,9% P=0,78).Before 
PMC, Group 1 had significantly higher Wilkins score 
(9,3±0,8(group 1) vs.8,5±0,6  (group2), p <0,001) , tight 
mitral valve area (MVA) (0,91±0,20 (group1) vs.0,99±0,20  
( group 2), P<0,05)and higher mean gradient (15,81±4,8 
The incidence of atrial fibrillation was significantly less 
frequent in group 2 than group 1. Systolic pulmonary artery 
pressure was significantly higher in group 1 than group 2. 
After PMC; The mitral valve area was increased; 2,10±0,26 
in group 1 vs.2,20±0,22 in group2  (P<0,05) and pulmonary 
pressure was decreased 31,89±13,35 in group1 
vs35,97±9,97 in group 2(P=0,026); however the MVA 
increase was similar into the 2 group (1,19±0,25 vs 
1,19±0,25 P =0,946).Concerning the final mean gradient , 
there was no significant difference between two groups. The 
rate of good immediate results was similar into two 
groups(97,9% vs.100% .P=0,241).There was no death , one 
case was presented a tamponnade, a moderated mitral 
regurgitation  was observed only in 4 patients of group 1 , 
but without significant difference.(2% in group 1 vs 0% in 
group 2 .P=0,174) . 
 
 
Table I: Baseline clinical and echocardiographic characteristics of the population, overall and according to subgroups 
  ovrall (n=215) Group 1 (n=148) Group 2(n=67) P 
Age (years) 47,53±12,81 49,70±12,23 42,76±12,85 P<0,001 
Female gender 79,5%(171) 75%(70) 88,1%(59) P=0,03 
NYHA functional class III–IV 97,2%(209) 95%(142) 95,6%(64) P=0,66 
Previous commissurotomy 18,6%(40) 24,3(36) 11,9%(8) P=0,78 
Atrial fibrillation 60%(129) 66%(99) 44,8%(30) P=0,002 
Wilkins score  9,13±0,88 9,38±0,85 8,52±0,63 P<0,001 
Mitral valve area (cm2) 0,93±0,20 0,91±0,20 0,99±0,2 P=0,01 
Mean gradient  (mmHg) 15,33±4,59 15,81±4,87 14,28±3,7 P=0,023 
Systolic pulmonary artery pressure 
(mmHg) 
57,13±17,31 58,84±17,92 53,66±15,37 P=0,031 
 
 
Table II :Results of percutaneous mitral commissurotomy overall in the 215 patients, and according to subgroups 
  Overall (n=215) 
Group 
1(n=148) 
Group 2( n=67) P 
echocardiographic characteristics         
Mitral valve area (cm²) 2,13±0,26 2,10±0,26 2,20±0,22 P =0,012 
Mitral valve area increase (cm²) 1,19±0,25 1,19±0,25 1,19±0,25 P =0,946 
Good immediate results (SM>1,5 et IM<2) 98,6%(212) 97,9%(145) 100%(67) P=0,241 
Mean gradient(mmHg) 5,14±1,88 5,30±1,96 4,78±1,63 P=0,059 
Mean gradient increase (mmHg) 10,18±4,33 10,50±4,49 9,49±3,91 P=0,116 
Systolic pulmonary artery pressure, (mmHg) 33,16±12,52 31,89±13,35 35,97±9,97 P=0,026 
Systolic pulmonary artery pressure increase 
(mmHg) 
23,97±12,67 26,95±12,32 17,39±10,87 P<0,001 
Bilateral complete commissural opening  72,5%(156) 69,6%(103) 79,1%(53)   
At least one commissure completely open 27,4%(59) 30,4%(45) 20,9%(14)   
In-hospital complications          
In-hospital mortality 0% 0% 0%   
Tamponade 0,4%(1) 0% 1,5%(1)   
Embolism 0% 0% 0%   
Mitral regurgitation grade ≥3 1,8%(4) 2%(4) 0% P=0,174 
Mitral valve replacement 0,4%(1) 0,6%(1) 0%   
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 Percutaneous mitral commissurotomy is now emerging 
as treatment at the first-line of mitral stenosis with favorable 
valvular anatomy, with good immediate results which are 
maintained in the medium and long term [7]. However, few 
studies have examined the feasibility and effectiveness of 
PMC for calcific mitral stenosis [8]. Our study describes 
characteristics and compares results of PMC of calcific 
mitral stenosis (MS) to mitral stenosis without 
calcifications.                                                                                                                               
Calcific MS is observed in older population than MS 
without calcifications; Indeed, in our study, the mean age of 
patients with calcific MS was 49, 7±12,2 vs.42,7±12,8. This 
age difference is also found in Murat Tuzcu study when the 
mean age is 61 years in calcific MS vs 47 years [9] ,and in 
Iung study  when the mean age is 58 ±13 years vs 45 ±15 
years respectively [10], and in the Kurudamannil study; 
46,2±10,3 years of calcific MS [11]. Although age is as an 
important factor involved in development of mitral 
calcification, male gender was cited as predisposing factor 
of calcifications [12], even if female gender is frequent, in 
our study, there are significantly more men in calcific MS 
group 1 compared to group 2. This greater proportion of 
men was also seen in Murat Tuzcu study (143women/30 
men for MS without calcifications vs.124 men/31women for 
calcificMS.)[9]                                                                                                                                                                    
Moreover, atrial fibrillation usually funded in patients with 
calcific MS, 66% of our patients with calcific MS were in 
atrial fibrillation versus 44.8% in the group of MS without 
calcifications. We found also this difference in the literature; 
in Iung study (50% had AF in calcific group  MSvs 33% in 
the no calcific MS group), and Tuzcu study (64% had AF in 
calcific MS group vs 35%in no calcific MS group)[9,10)]. 
Atrial fibrillation is more frequent because the patient are 
older, with MS tighter and a left atrium more dilated 
[10].Wilkins score was significantly higher in calcific MS 
group versus non- calcific MS Group, it’s logical because 
the degree of calcification is one of 4 criteria of score but 
also the high degree of calcification is associated to 
valvulargreater thickness, reduced valve mobility and 
relatively severe extent of subvalvular disease [13].  In 
Murat Tuzcu study, the Wilkins score was 8, 9 in calcific 
MS group versus 6, 8 in no calcific MS group [9]. 
Mitral stenosis was more severe in our patients compared 
to no calcific MS group, with a high percentage of mitral 
stenosis very tight (mitral area < 1 cm²): ²); 53,3% versus 
32,8%; like MuratTuzcu study:  0,8cm² for calcific MS vs 
0,9cm² in control group[9]. Mitral stenosis is tighter even 
the degree calcification is high, according to Julien Dreyfus 
study where there had a highly significant difference 
between the three sub- groups studied ( p <0.0001);  mitral 
area at 1,09cm²in group with MS without calcifications, MA 
at 1,05cm² in group with no significant commissural 
calcification, and  MA at 0,95cm²in group with significant 
commissural calcification[3]. We conclude that calcific MS 
affects older patients, often in atrial fibrillation and mitral 
stenosis is tighter with altered valves .A good result is 
defined by combination of a mitral functional surface       ≥ 
1.5 cm ² and a small mitral regurgitation (MR). In our study, 
the rate of good immediate results was very good: 97.9%, 
below the rate of success in non-calcific MS group is 100 %, 
there is no significant difference. This success rate is less 
important in other studies treating calcific MS; It was 79% 
in Iung study and 85.4% in kurudamannil study [10, 11]. 
Indeed , PMC during the first 10 years of experience ,as our 
study has been done on calcific MS dilated from 2011 to 
2015 , so after 25 years of experience in our department. 
Furthermore, the listing of calcifications was not the same in 
our study compared to other studies, we have classified 
calcifications by tranthoracic and trans 
oesophagicechocardiograpy while the authors were based on 
visualization of calcifications by fluoroscopy and 
angiography [10,11,14]. Moreover, the success rate was 
significantly lower in Tuzcu study compared to our results 
and those of other studies; 52% in calcific MS group, This 
low success rate is partly due to the difference in the 
definition of a good immediate result for Tuzcu , unlike 
other authors, the appearance of significant MR grade was a 
failure criterion[9]. 
 
















        Before After     
TUZCU 1994 [9] 155 61±1 8,9±0,2 0,8±0,02 1,8±0,06 52   
IUNG 2000[10] 422 58±13   1,01±0,22 1,74±0,30 79 4 
KURUDAMANNIL 
41 46,2±10,3 9,2±0,9 0,9±0,2 1,7±0,3 85,4 2,4 
1999[11] 
Our study  
( between 2011-2015) 
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MVA after PMC was more higher in patients with a 
Wilkins score<8 (2,21 cm²), than patients with a score 
between 9 and 11 (2,09cm²). The study of individual 
parameters of this score shows that immediate result of 
PMC is strongly influenced by degree of valvular mobility, 
and by association of calcifications [13]. However, a major 
limitation of Wilkins score is the lack of study of 
commissure morphology. The main mechanism of action of 
PMC is separation of the fused commissure; including the 
presence of significant fibrosis or calcifications commissure, 
will constitute a failure of the procedure factor. In Bezdah 
study:  commissure morphology has significantly influenced 
the result of PMC: MVA was 1,83cm² with no commissural 
calcifications, and dropped to 1,5cm² when commissure was 
calcified [13]. 
PMC safety, and immediate as well as long-term efficacy 
have been widely demonstrated [15].  PMC remains a safe 
procedure, which does not expose patient to increased risk 
of complications. But it must still emphasize a trained and 
experienced operator, especially when there is a highly 
calcified valve. In our study, no deaths were directly 
induced by the procedure, one case of tamponade in no 
calcific MS group. The mortality in the literature, although it 
is slightly higher compared to our study , remains below 
2%( in Iung study; 1,2% with a tamponade in 0,5% of  cases 
; in Murat Tuzcu study; 1,9% with a cardiogenic shock, a 
tamponade and a perforation of the left ventricle)[9,10] .  
We deployed no cases of thromboembolism in our study. In 
theory, the presence of calcifications fears in per- procedure 
migrating calcareous emboli and the occurrence of stroke, 
this has not been demonstrated [10,14,15].Mitral 
regurgitation is a serious and feared complication of CMP. 
In our study: 4 cases of severe MR in calcific MS and no 
cases in no calcific MS group; Iung had 4% of severe 
MR[10], and kurudamannil  had 2,4% of severe MR[11].  
Several predictors of MR were analyzed by 
echocardiography[16,17].In fact, Padial LR has also 
established a Risk Score occurrence of MR ( Mitral 
regurgitation echoscore ) integrating study of thickening 
valve , distribution of fibrosis and calcifications in each 
leflets , the study of commissures and the extent of 
subvalvular disease. This score is more difficult to study 
than Wilkins score,  proved superior in predicting  
occurrence of severe MR[18,19].  
V. CONCLUSION 
Percutaneous mitral commissurotomy must be indicated 
as  first-line treatment of patients with  calcific mitral 
stenosis( Grad 1,2,3), because the results in this group was 
similar to the group without calcifications.  So though our 
experience  and in our context ,The PMC of patients with 
calcific mitral stenosis allow us to the management of 
patients with a difficult socio-economic status, who don’t 
have access to the surgery .  Prospective studies would 
better understand the predictors of immediate and long-term 
results of the PMC in the calcific MS, for a better selection 
of patients. 
REFERENCES 
[1] HorskottD,Neihues R et Strauer BE. Pathomorphological aspects, 
aetiology and natural history of acquired mitral valve stenosis.Eur 
Heart J 1991;12(SuppB):55-60.   
[2] Luxereau P, Iung B, Cormier B et Vahanian A. Rétrécissement 
mitral.Encycl Med Chir(Elsevier, Paris), Cardiologie-angiologie,11-
010-A-10,1998,11p.  
[3] Julien Dreyfus, Claire Cimadevilla, Virginia Nguyen1, Eric Brochet, 
Laurent Lepage, Dominique Himbert, Bernard Iung, Alec Vahanian, 
David Messika-Zeitoun. Feasibility of 
percutaneousmitralcommissurotomy in patients with commissural 
mitral valve calcification. European Heart Journal (2014) 35, 1617–
1623. 
[4] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, 
Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, 
Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler 
G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, 
Windecker S, Zamorano JL, Zembala M, Bax JJ, Baumgartner H, 
Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai 
D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, 
Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki 
A, Vahanian A, Windecker S Popescu BA, Von Segesser L, Badano 
LP, Bunc M, Claeys MJ, Drinkovic N, Filippatos G, Habib G, 
Kappetein AP, Kassab R, Lip GY, Moat N, Nickenig G, Otto CM, 
Pepper J, Piazza N, Pieper PG, Rosenhek R, Shuka N, 
Schwammenthal E, Schwitter J, Mas PT, Trindade PT, Walther T. 
Guidelines on the management of valvular heart disease (version 
2012): the Joint Task Force on the Management of Valvular Heart 
Disease of the European Society of Cardiology (ESC) and the 
European Association for Cardio-Thoracic Surgery (EACTS). Eur 
Heart J 2012;33:2451–2496. 
[5] . Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, 
O’Gara PT, O’Rourke RA, Shah PM, Bonow RO, Carabello BA, 
Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, 
Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah 
PM, Shanewise JS, Smith SC Jr, Jacobs AK, Buller CE, Creager MA, 
Ettinger SM, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, 
Page RL, Tarkington LG, Yancy CW Jr. ACC/AHA 2008 Guideline 
update on valvular heart disease: focused update on infective 
endocarditis: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice 
Guidelines: endorsed by the Society of Cardiovascular 
Anesthesiologists, Society for Cardiovascular Angiography and 
Interventions, and Society of Thoracic Surgeons. Circulation 
2008;118:887–896. 
[6] Padial LR, Abascal VM, Moreno PR, Weyman AE, Levine RA, 
Palacios IF. Echocardiography can predict the development of severe 
mitral regurgitation after percutaneous mitral valvuloplasty by the 
Inoue technique. Am J Cardiol 1999; 83:1210–1213. 7. Padial LR, 
Freitas N, Sagie A, Newell JB,Weyman AE, Levine RA, Palacios IF. 
Echocardiography can predict which patients will develop severe 
mitral regurgitation after percutaneous mitral valvulotomy. J Am 
CollCardiol 1996;27:1225–1231. 
[7] Ben ferhatM,AyariM,Maatouk F et al. Percutaneous balloon versus 
surgical closure and open mitral commissurotomy. Seven years 
follow-up results of a randomized trial. Circulation .1998;97:245-50.    
[8] Cannan CR et al.echocardiographieassessement of commissural 
calcium: a simple predictor of outcome after percutaneous mitral 
balloon valvulotomy.JAmcollcardiol 1997;29:175-80. 
[9] Tuzcu EM et al. Percutaneous mitral balloon in patients with calcific 
mitral stenosis: immediate and long term outcome .JACC Vol . 23. 
No. 7 June 1994 1604-9.  
[10] Iung B, GarbarzE,Doutrelant  L,  Berdah P; Mechaud P, Frarah B, 
Mokhtari M, Makita Y, Michel PL, Luxereau P, Cormier B et 
VahanianA.late results of percutaneous mitral commissurotomy for 
calcific mitral stenosis. J Am Cardiol 2000;Vol 85;Issue 11:1308-
1314. 
 
[11] kurudamannilAA,BaskaranC,Sriram R, 
HansogiSS,GurijlaS.Percutaneoustransvenous mitral 
commissurotomy for significant calcific mitral stenosis :utility of the 
stepwise balloon dilatation technique and follow-up 
results.JInvasCardiol 1999;11:345-350.  
 
                                                                                International Journal of New Technology and Research (IJNTR) 
                                                                           ISSN:2454-4116,  Volume-2, Issue-9, September 2016  Pages 53-57 
 
                                                                            57                                                                         www.ijntr.org 
 
[12] Porte J-M,Checrallah E et Acar J. Rétrécissement mitral.In: Acar J et 
AcarC.Cardiopathie valvulaire acquise.Paris:Flammarion 
sciences;1993.p.147-169.  
[13] BezdahL,Drissa M.A, Kasri R,  Baccar H, 
BelhaniA.paramètreséchocardiographiques prédictifs du résultat 
immédiat de la commisuurotomie mitrale percutanée.LaTunésie 
Médicale-2007;Vol 85 (n 06):479-484.  
[14] Zhang HP,Allen JW, Lau FIK, Ruiz CE.Immediate and late outcome 
of percutaneous balloon mitral valvotomy in patients with 
significantly calcified valves.Am Heart J 1995;129:501.  
 
[15] Iung B, Cormier B, Ducimetiere P, Porte JM, Nallet O, Michel PL, 
Acar J, Vahanian A. Immediate results of percutaneous mitral 
commissurotomy.Apredictivemodel on a series of 1514 patients. 
Circulation 1996;94:2124–2130. Ben Farhat M, Ayari M, Maatouk F, 
Betbout F, Gamra H, Jarra M, Tiss M, HammamiS,Thaalbi R, Addad 
F. Percutaneous balloon versus surgical closed and open mitral 
commissurotomy: seven-year follow-up results of a randomized trial. 
Circulation 1998;97:245–250.  
[16] Abascal VM, Wilkins GT, Choong GY, Block PC, Palacios IF, 
Weyman AE .Mitral regurgitation after percutaneous mitral 
valvuloplasty in adults:evaluation by pulsed Doppler 
echocardiography , J Am CollCardiol 1988 ; 11 : 257-63.  
[17] Roth BR, Block PC, Palacios IF .Predictors of increased mitral 
regurgitation after percutaneous mitral balloon 
valvulotomy.CathetCardiovascDiagn1990 ; 20: 17-92.  
[18] Pradial LR, Freitas N, Sagie A et al .Echocardiography can predict 
wich patients wil develop severe mitral regurgitation after 
percutaneous mitral valvulotomy .J AMmCollCardiol 1996; 27:1225-
31.  
[19] Herman HC, Lima JAC, Feldman T, et al. For the North American 
Inoue-balloon investigators: Mechanisms and outcomes of severe 
mitral regurgitation. J Am CollCardiol 1993; 22:783-789.  
 
